NICE rebuffs Nplate

The U.K.'s NICE issued a preliminary appraisal recommending against the use of Nplate romiplostim from Amgen Inc. (NASDAQ:AMGN) to treat chronic idiopathic thrombocytopenic purpura. In its appraisal, the agency said evidence for Nplate's relative effectiveness compared with other active treatments is "lacking." ...